Ocean Biomedical Reports Receipt Of Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q

OCEAN BIOMEDICAL, INC. 0.00%

OCEAN BIOMEDICAL, INC.

OCEA

1.47

0.00%

Ocean Biomedical has determined to restate its consolidated financial statements as of and for the quarters ended March 31, 2023 and June 30, 2023. Nasdaq indicated that the company must, no later than January 22, 2024, submit a plan to regain compliance with respect to the filing requirement.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via